Ispire Malaysia Attains ISO Certification, Avoiding 25% Transportation Tariffs

Business by 2FIRSTS.ai
Jan.05.2024
Ispire Malaysia Attains ISO Certification, Avoiding 25% Transportation Tariffs
Ispire Malaysia obtains ISO certifications, CEO Michael Wang says having its own factory will increase profit margins.

According to an announcement on the official website of Ispire on January 4th, the company has declared that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd, has successfully obtained certifications for ISO9001:2015 Quality Management System, ISO14001:2015 Environmental Management System, and ISO13485:2016 Medical Device Quality Management System for its manufacturing facility in Malaysia.

 

Michael Wang, the CEO of the company, stated that having our own factory will allow us to achieve greater profits in product assembly. Furthermore, the products produced by our company in Malaysia and shipped to the United States are not affected by tariffs, which creates favorable conditions for increasing gross profit margins.

 

Michael Wang stated, "We have received our initial orders and are rapidly entering the production preparation phase. By establishing production facilities in Malaysia, we not only avoid the 25% tariffs incurred from shipping from China, but also improve our gross profit margin."

 

In order to reduce tariff costs, it is predicted that Ispire will further shift its production processes to Malaysia.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Spain’s Competition Authority Questions Disposable Vape Ban
Spain’s Competition Authority Questions Disposable Vape Ban
Spain’s National Commission on Markets and Competition (CNMC) has issued an opinion on the draft reform of the Tobacco Law proposed by the Ministry of Health, urging reconsideration of several measures. These include a proposed ban on disposable e-cigarettes and the full alignment of vaping products with traditional tobacco regulation.
Dec.17 by 2FIRSTS.ai
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
IMiracle  Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle announces significant R&D progress in 2025, with over 2,200 patent applications globally and 900 authorized patents.
Dec.18 by 2FIRSTS.ai
Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao analyzes post-Operation Absolute Resolve geopolitics and the rise of “U.S.-referenced regulatory alignment” in South America’s novel tobacco market as U.S. influence grows. Using regulatory reliance, digitalized enforcement, and industrial shifts, he assesses how rule redesign may alter market access, competition, and supply chains, asking how firms can find durable certainty as order is rewritten.
Jan.06 by 2Firsts Perspectives
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai